VenstraMedical

About

VenstraMedical develops a low-profile, full-flow percutaneous ventricular assist device (pVAD) for patients in cardiogenic shock or undergoing high-risk coronary interventions.

Mission

VenstraMedical is a cardiovascular medical device company advancing a next-generation percutaneous ventricular assist device (pVAD) that collapses into a 9-French catheter for minimally invasive insertion and can deliver up to 7 L/min of cardiac output once deployed. Protected by eight issued patents, the catheter-based pump is engineered to provide complete ventricular unloading and improved hemodynamic stability, aiming to enhance performance, safety, and ease of use over existing systems. The company recently published supportive pre-clinical data in the ASAIO Journal and presented findings at Transcatheter Cardiovascular Therapeutics (TCT). VenstraMedical previously secured a US$1 million grant from MTPConnect’s Targeted Translation Research Accelerator, backed by Australia’s Medical Research Future Fund. With the global pVAD market estimated at more than US$2 billion annually and growing, VenstraMedical intends to move rapidly toward clinical trials. The fresh capital from Highcroft Capital will be used to accelerate product development and regulatory preparation. VenstraMedical operates out of Newcastle, Australia, with additional presence in Eden Prairie, Minnesota.

Quick Facts